A Service of the National Library of Medicine and the National Institutes of Health
RESEARCH ON ATHEROSCLEROTIC DISEASE & OXIDATIVE STRESS AT PUBMED
Targeting Cellular Antioxidant Enzymes for Treating Atherosclerotic Vascular Disease. 2013 Mar;21(2):89-96.
Abstract: Atherosclerotic vascular dysfunction is a chronic inflammatory process that spreads from the fatty streak and foam cells through lesion progression. Therefore, its early diagnosis and prevention is unfeasible. Reactive oxygen species (ROS) play important roles in the pathogenesis of atherosclerotic vascular disease. Intracellular redox status is tightly regulated by oxidant and antioxidant systems. Imbalance in these systems causes oxidative or reductive stress which triggers cellular damage or aberrant signaling, and leads to dysregulation. Paradoxically, large clinical trials have shown that non-specific ROS scavenging by antioxidant vitamins is ineffective or sometimes harmful. ROS production can be locally regulated by cellular antioxidant enzymes, such as superoxide dismutases, catalase, glutathione peroxidases and peroxiredoxins. Therapeutic approach targeting these antioxidant enzymes might prove beneficial for prevention of ROS-related atherosclerotic vascular disease. Conversely, the development of specific antioxidant enzyme-mimetics could contribute to the clinical effectiveness.
Consider PROTANDIM®, The Nrf2 Activator “Game Changer”!
A fundamental synergistic new approach to antioxidant therapy!
Clinical studies of Protandim® resulted in:
30% Increase in SOD Production
54% Increase in Catalase Production
300% Increase in Glutathione Peroxidase Production
Protandim® is the ONLY product that has been scientifically proven to reduce oxidative stress by 40% in 30 days.
Watch ABC Primetime Investigative Report on Protandim www.ABCreport.net
Disclaimer: PROTANDIM DOES NOT CLAIM TO TREAT, MITIGATE, DIAGNOSE, CURE, OR PREVENT ANY DISEASE.